Please provide your email address to receive an email when new articles are posted on . Annual incidence of asymptomatic pulmonary fibrosis in relatives of those with familial interstitial pneumonia ...

PPF is identified by decline in lung function, worsening symptoms, and increased fibrosis on imaging, with variable criteria across studies. Risk factors for PPF include older age, male sex, smoking, ...

A new antifibrotic option for patients living with idiopathic pulmonary fibrosis (IPF), systemic sclerosis-associated ...

Interstitial lung disease (ILD) causes significant morbidity and mortality in patients with systemic autoimmune rheumatic diseases. Patients at high risk of ILD should be screened using ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider Jeffrey J. Swigris, ...

After being hospitalized for three months with COVID-19 and double pneumonia in 2020, Houston police officer Hito Bazan awoke one morning to discover that he couldn't talk, eat, walk, or most ...

The FDA has expanded the approval of Jascayd (nerandomilast), an oral phosphodiesterase 4 (PDE4) inhibitor, to include treatment of progressive pulmonary fibrosis in adults.

BERKELEY, Calif.--(BUSINESS WIRE)--IMVARIA Inc., a health tech company pioneering AI-driven digital biomarker solutions, today announced data from a study evaluating the company’s lead non-invasive ...

The FDA has approved Jascayd (nerandomilast) as a treatment for a second lung disease, progressive pulmonary fibrosis, following the drug’s initial approval in October 2025 as a treatment for ...